The company said that the Livian cardiac resynchronization therapy defibrillator (CRT-D), which is available in high-energy and standard-energy models, enables clinicians to customize therapy based on a patient’s individual needs. Livian also offers clinicians technology to help manage heart failure patients with frequent atrial arrhythmias.
Jim Tobin, president and CEO of Boston Scientific, said: “This next-generation CRT-D offers physicians in Europe and elsewhere even more flexibility for tailoring therapy to each patient. It is a testament to our ongoing commitment to providing innovative solutions for the treatment of heart failure.”